Therapeutic Apheresis: Market Research Report

September 2011 | 126 pages | ID: T83BE177834EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the US market for Therapeutic Apheresis in US$ Thousand by the following procedures: Photopheresis, Plasmapheresis, Erythrocytapheresis, Plateletpheresis, Leukapheresis, and Lipidpheresis.

The specific end-use segments analyzed are Neurology Disorders, Hematology & Oncology Disorders, Rheumatology Disorders, and Others.

Annual estimates and forecasts are provided for the period 2009 through 2017.

Also, a six-year historic analysis is provided for this market.

The report profiles 10 companies including many key and niche players such as CaridianBCT, Inc., Fenwal, Inc., Fresenius Medical Care North America, Haemonetics Corporation, HemaCare Corporation, and Therakos, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Photopheresis
Plasmapheresis
Erythrocytapheresis
Plateletpheresis
Leukapheresis
Lipidpheresis

2.MARKET OUTLOOK

Market Trends at a Glance
Current & Future Analysis
Photopheresis: A Segment with High Growth Rate Owing to Increasing Demand in Off-label Indications
Plasmapheresis: The Method of Choice for Plasma Collection

Table 1. Plasma Collection Methods: Percentage Breakdown by Fractionation and Extraction from Whole Blood (2000 Vs. 2010) (includes corresponding Graph/Chart)

Table 2. Leading Plasma Product Companies (2009): Market Share Breakdown for Baxter, CSL, Grifols/ Talecris, Biotest, and Others (includes corresponding Graph/Chart)

Plateletpheresis Emerges as the Treatment of Choice
Increase in Number of Platelet Donors Owing to Apheresis Procedure
Pediatrics: An Unexplored Domain in Therapeutic Apheresis
Vendors’ Attitude Hampers Growth Prospects of Therapeutic Apheresis
Technological Advancements and Novel Indications to Augur well for the Therapeutic Apheresis Market
Lack of Awareness among Patients Restrains Market Growth
Challenges in the Therapeutic Apheresis Market
Need to Develop Inexpensive Apheresis Therapies
Scarcity of Qualified Donors
Challenges in the Unexplored Pediatrics Segment
Therapeutic Apheresis: An Overview of Regulatory Environment and Reimbursement Scenario
New Reimbursement Policies to Create Growth Opportunities for Therapeutic Apheresis
Medicaid Coverage for Therapeutic Apheresis by Various Conditions

Table 3. APC* Payment Rates For Different Therapeutic Apheresis Procedures (2009-2010)

3.COMPETITIVE SCENARIO

Japan-based Terumo Corp. Acquires CaridianBCT, the Leading Player in Therapeutic Apheresis Market
Market Share Trends
Therapeutic Apheresis in Neurology Disorders: Market Shares by Revenues

Table 4. US Market for Therapeutic Apheresis in Neurological Disorders (2010): Market Share Breakdown of Revenues by Company for Caridian BCT, Fresenius- Kabi LLC, Haemonetics, and Others (includes corresponding Graph/Chart)

Therapeutic Apheresis in Neurology Disorders: Market Shares by Number of Procedures

Table 5. US Market for Therapeutic Apheresis in Neurological Disorders (2010): Market Share Breakdown of Number of Procedures by Company for CaridianBCT, Fresenius-Kabi, Haemonetics, and Others (includes corresponding Graph/Chart)

Therapeutic Apheresis in Hematology and Oncology Disorders: Market Share by Revenues

Table 6. US Market for Therapeutic Apheresis in Hematology and Oncology Disorders (2010): Market Share Breakdown of Revenues by Company for CaridianBCT, Therakos, Fresenius-Kabi, and Others (includes corresponding Graph/Chart)

Therapeutic Apheresis in Hematology and Oncology Disorders: Market Share by Number of Procedures

Table 7. US Market for Therapeutic Apheresis in Hematology and Oncology Disorders (2010): Market Share Breakdown of Number of Procedures by Company for CaridianBCT, Fresenius-Kabi, and Others (includes corresponding Graph/Chart)

4.THERAPEUTIC APHERESIS: A SEGMENTAL OVERVIEW

Apheresis and Therapeutic Apheresis: The Difference
Therapeutic Apheresis: An Introduction
Applications of Therapeutic Apheresis
Emerging Applications of Therapeutic Apheresis
Uses of Apheresis and Therapeutic Apheresis
Overview of Therapeutic Apheresis
Blood Components
Therapeutic Apheresis Process
Duration, Frequency, and Efficiency of Therapeutic Apheresis
Segregation of Blood Components
Centrifugation
Filtration
History of Therapeutic Apheresis Market
Therapeutic Apheresis Versus Dialysis

Table 8. Global Hemodialysis Market by Leading Players (2009): Market Share Breakdown for Fresenius Medical, Gambro, Baxter, and Others (includes corresponding Graph/Chart)

Categories of Indications for Therapeutic Apheresis
Types of Therapeutic Apheresis Procedures
Photopheresis
Functioning of THERAKOS™, a Typical Photopheresis System
Plasmapheresis
Plasma Exchange and Plasmapheresis: The Difference
Therapeutic Plasma Exchange (TPE) or Plasma Exchange
TPE: Abnormal Components Removed from Blood
Plasmapheresis: Potential Uses Discovered in the Early Years
Potential Use of Plasmapheresis in Select Diseases Discovered in the Early Years
Erythrocytapheresis
Plateletpheresis
Leukapheresis
Lipidpheresis
Cytapheresis
Therapeutic Apheresis is Remedial for Various Diseases
Cost of Select Therapeutic Apheresis Procedures: An Overview

1. PHOTOPHERESIS IN GVHD (GRAFT-VERSUS-HOST DISEASE)

2. LIPID APHERESIS (LDL APHERESIS)

3. PLASMAPHERESIS AND OTHER PROCEDURES

Therapeutic Apheresis: What is the Risk Involved?
Replacement Fluid in Therapeutic Apheresis
Replacement Fluids Used in Therapeutic Apheresis
Various Replacement Fluids
Select Replacement Fluids and their Limitations
Fluid Balance in Fluid Replacement

Table 9. Volume Exchange of Plasma Constituents

Table 10. Removal of IgM and IgG by Plasma Exchange Volume

Table 11. Therapeutic Apheresis: Percentage Decrease and Restoration of Blood Components

Complications Involved and Suggested Treatment in the Therapeutic Apheresis Procedure
Therapeutic Plasmapheresis with Fresh Frozen Plasma (FFP) Replacement
Sources of Blood Plasma
Plasma Donations

Table 12. Number of Plasma Donation Centers in US and Europe: 2006-2008 (includes corresponding Graph/Chart)

Table 13. Number of Plasma Donations in US and Europe (In Thousands): 2006-2008 (includes corresponding Graph/Chart)

Table 14. Number of Plasma Donations Required Annually by Disease Type in the US: 2009 (includes corresponding Graph/Chart)

Pre-requisites for Plasma Donors
Select IQPP-authorized Plasma Collection Centers (US)
CFA – An Effective way to Pull Up Cold Hemagglutinin Disease
Trima Accel, the most Widely Used Platelet Collection Equipment in the US

5.PRODUCT AND TECHNOLOGICAL DEVELOPMENTS

Health Canada Licenses CaridianBCT’s new Protocol for Spectra Optia® Apheresis System
Fenwal’s Amicus System Obtains CE Mark Certification for a Therapeutic Plasma Exchange Protocol
CaridianBCT Releases Spectra Optia Apheresis System Version 5
CaridianBCT Introduces Trima Accel® Version 6
CaridianBCT Introduces RBCX Protocol in Canada
CaridianBCT Introduces Spectra Optia® System Mononuclear Cell Collection Protocol
Golden Meditech Company to Launch Model 3000H Plasma Exchange System
HemoCleanse to Develop Novel Plasmapheresis Device
Aethlon Develops a New Device to Remove HIV
Therapeutic Plasmapheresis for Treatment of Autoimmune Diseases

6.RECENT INDUSTRY ACTIVITY

Fenwal’s Amicus System Obtains CE Mark Certification for a Therapeutic Plasma Exchange Protocol
Terumo Corp. Completes Acquisition of CaridianBCT
Fenwal Obtains FDA Approval for Collection of InterSol® Preserved Platelets using Amicus® Cell Separator
FDA Clears Fenwal’s Software for Autopheresis-C® System
HemaCare Inks Commercial Cell Therapy Collection Agreement with Dendreon
Cerus Receives CE Mark Approval for the Latest Configuration of INTERCEPT Blood System
Therakos Obtains FDA Approval for THERAKOS™ CELLEX™ Photopheresis System
Biotest Acquires Talecris’ Plasma Collection Unit
CaridianBCT Receives CE Mark Approval for Expanded Mirasol Pathogen Reduction Technology System
Gambro Changes Name to CaridianBCT
Therakos Obtains CE Mark for THERAKOS™ CELLEX™ Photopheresis System in Europe
Verax Biomedical Gains CE Mark for Platelet PGD® Test

7.STRATEGIC CORPORATE DEVELOPMENTS IN THE RECENT PAST

OccuLogix Puts Off Clinical Development of RHEO™ System
Baxter Divests Transfusion Therapies Business
SCSG Gets Hold of Fresenius Medical Care Extracorporeal Alliance
Rheologics Technologies Takes Over Cardiodyne Electronics
Biotest Obtains Plasma and Protein Business Unit of Nabi BioPharmaceuticals
Gambro BCT Receives FDA Clearance for Spectra Optia System
MedaSorb Receives Rights for Blood Processing
Fresenius Medical Care Takes Over Renal Care
Haemonetics Signs Acquisition Agreement with Arryx
Cerus Receives Rights for INTERCEPT Blood System
Blood Systems to Implement Gambro BCT 7-day platelets
Renal Care Pockets Bay Area Mobile Apheresis Program
Haemonetics Pacts with FMCEA
PhereSys and ACGT Ink Consulting Services Pact
CHF Forges a Service Provider Pact with FMCEA
Otsuka America Inks a Pact with HemaCare
Gambro Acquires Ivex
Fresenius HemoCare Becomes a Part of Fresenius Kabi
Alpha Therapeutic Sells Assets to Probitas Pharma and Baxter
Gambro Signs Agreement with The American Red Cross
Gambro Receives Contract from NBS
FMC-EA Inks Deal with Allina Hospitals
Gambro Starts a New Company, Navigant Biotechnologies
Gambro’s Vista™ Receives Approval from FDA
Gambro’s New Anticoagulant Solution Receives FDA Approval
Gambro BCT Receives FDA Clearance for New Filter Tubing Sets Developed by Pall
Gambro Launches Trima Accel Automated Blood Collection System
Fresenius HemoCare Acquires PROSORBA® Column from Cypress Bioscience
Gambro Buys the Assets of Sanguistech
Haemonetics Inks Purchase Agreement with Alpha Therapeutic Corp
Gambro Joins Forces with the Walter Reed Army Institute of Research
Gambro Collaborates with Dendreon for Commercialization of Therapeutic Vaccines
Gambro AB Enters into a Partnership with Sangart
WakeMed Awards a Contract to HemaCare’s Subsidiary
HemaCare’s Subsidiary Coral in Agreement with CMH
BioTransplant Inks an Exclusive Distribution Agreement with Gambro BCT
Gambro BCT Receives US Patent for its Pathogen Inactivation Technology
Gambro’s Trima Receives Approval from The Japanese Red Cross Society
Gambro BCT Test Launches the Vista™ Information System

8.FOCUS ON SELECT GLOBAL PLAYERS

CaridianBCT, Inc.
CaridianBCT’s Product and Technological Innovations: 1988-2009
Fenwal, Inc.
Fresenius Medical Care North America (FMCNA)
Haemonetics Corp.
HemaCare Corp.
Therakos, Inc.

9.MARKET PERSPECTIVE

Table 15. The US Recent Past, Current & Future Market Analysis for Therapeutic Apheresis by Procedure – Photopheresis, Plasmapheresis, Erythrocytapheresis, Leukapheresis, Lipidpheresis, and Plateletpheresis Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 16. The US Historic Review for Therapeutic Apheresis by Procedure – Photopheresis, Plasmapheresis, Erythrocytapheresis, Leukapheresis, Lipidpheresis, Immunoadsorption, and Plateletpheresis Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 17. The US 15-Year Perspective for Therapeutic Apheresis by Procedure – Percentage Breakdown of Revenues for Photopheresis, Plasmapheresis, Erythrocytapheresis, Lipidpheresis, Plateletpheresis, Leukapheresis, and Immunoadsorption Markets Independently Analyzed for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 18. The US Recent Past, Current & Future Market Analysis for Therapeutic Apheresis by Disorder Type – Hematology and Oncology, Neurology, Rheumatology, and Other Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 19. The US Historic Review for Therapeutic Apheresis by Disorder Type – Hematology and Oncology, Neurology, Rheumatology, and Other Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 20. The US 15-Year Perspective for Therapeutic Apheresis by Disorder Type – Percentage Breakdown of Revenues for Hematology and Oncology, Neurology, Rheumatology, and Other Markets Independently Analyzed for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

10.APPENDIX

Reported Uses of Therapeutic Apheresis
Competitive Landscape
Total Companies Profiled: 10 (including Divisions/Subsidiaries - 11)
Region/CountryPlayers
The United States
Japan